Advanced LC-MS technology for enhanced HCP detection in complex biotherapeutics
Host cell proteins (HCPs) are impurities in biotherapeutics that can impact drug quality and patient safety. Common methods like ELISA and LC-MS often fall short in detecting low-abundant HCPs, which pose risks to drug efficacy and stability.
Our latest article introduces an advanced LC-MS technology capable of detecting low-abundant HCPs, with two case studies demonstrating its effectiveness.
Read the full article to learn how this innovation enhances HCP detection and improves biotherapeutic safety and quality.
Host cell proteins (HCPs) are impurities in biotherapeutics that can impact drug quality and patient safety. Common methods like ELISA and LC-MS often fall short in detecting low-abundant HCPs, which pose risks to drug efficacy and stability.
Our latest article introduces an advanced LC-MS technology capable of detecting low-abundant HCPs, with two case studies demonstrating its effectiveness.
Read the full article to learn how this innovation enhances HCP detection and improves biotherapeutic safety and quality.
Share article
Related Content